StockNews.AI
JNJ
StockNews.AI
215 days

U.S. Cancer Biopsy Market and Competition Analysis, 2025-2030, Featuring Key Players - BD, IZI Medical Products, Johnson & Johnson Services, Argon Medical Devices, Spectra Medical Devices & More

1. U.S. cancer biopsy market expected to reach $20.18 billion by 2030. 2. CAGR of 10.8% anticipated, driven by liquid biopsy and early detection technologies. 3. Johnson & Johnson is a key player in the U.S. cancer biopsy market. 4. Rising cancer prevalence and geriatric population will boost market growth. 5. Multi-cancer early detection technologies show promise for future cancer diagnostics.

8m saved
Insight
Article

FAQ

Why Bullish?

The growth of the cancer biopsy market can positively affect JNJ’s position in this field.

How important is it?

The significant market growth represents a lucrative opportunity for JNJ's operations.

Why Long Term?

As cancer rates rise, JNJ’s ongoing innovations will increasingly benefit over time.

Related Companies

JNJ
Dublin, Jan. 16, 2025 (GLOBE NEWSWIRE) -- The "U.S. Cancer Biopsy Market Size, Share & Trends Analysis by Type, Cause, and Site, 2025-2030" report has been added to ResearchAndMarkets.com's offering.The U.S. cancer biopsy market size is expected to reach USD 20.18 billion by 2030, registering a CAGR of 10.8% from 2025 to 2030. The growth of the U.S. cancer biopsy market is attributed to the rise in the adoption of biopsies based on multi-parametric magnetic resonance imaging and the increasing popularity of image-guided needle biopsies in precision medicine applications. The liquid biopsy industry is anticipated to expand at an exponential rate in the coming years, wherein increasing investments and strategic initiatives by the companies involved in biopharmaceutical manufacturing & genomic data analysis are anticipated to play a central role. In April 2022, Global Brain invested in Craif, Inc. to develop a novel noninvasive urinary liquid biopsy for the early detection of cancer.Furthermore, the advent of liquid biopsies, rising clinical implementation of biopsies, and advancements in quality & payment pertaining to genetic cancer diseases are the factors expected to boost the market growth in the coming years. The increasing prevalence of cancer and the growing geriatric population are also likely to fuel market growth.Moreover, the advent of blood-based multi-cancer early detection (MCED) technologies is going to offer lucrative opportunities during the forecast period. MCED represents a paradigm shift in how cancers will be diagnosed and treated in the future. The great promise of MCED is that it will enable clinicians to convert from screening a few cancers to screening individuals for many cancers.Companies such as GRAIL, Exact Sciences Corporation are developing MCED tests. In addition, the National Cancer Institute (NCI) is looking at ways to study and evaluate MCED tests. NCI is currently designing clinical trials & other research opportunities for MCED tests, and recently issued a request for information from test developers on their readiness to participate in research initiatives.Key companies operating in the U.S. cancer biopsy market have adopted several strategic initiatives to reinforce their market presence. Major undertakings by the market participants are mergers & acquisitions, collaborations & partnerships, regional expansions, and new product launches. For instance, in April 2022, Medtronic entered into collaboration with GE Healthcare to address the increasing need for outpatient care. Under this initiative, customers can access financial solutions, extensive product portfolios, and exceptional services.U.S. Cancer Biopsy Market Report Highlights The fine-needle aspiration segment dominated the market with the largest revenue share of 32.2% in 2024, driven by the increasing prevalence of cancer and a growing preference for minimally invasive procedures.The screening & monitoring segment dominated the market with the largest revenue share in 2024, attributable to the rising demand for regular health check-ups and early cancer detection.The breast segment held a significant share of the market in 2024, driven by the rising incidence of breast cancer. As one of the most diagnosed cancers among women, breast cancer needs frequent diagnostic assessment, including biopsies, to determine the presence and stage of the disease. Why should you buy this report? Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.Competitive Landscape: Explore the market presence of key players worldwide.Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. This report addresses: Market estimates and forecasts from 2018 to 2030Growth opportunities and trend analysesSegment and regional revenue forecasts for market assessmentCompetition strategy and market share analysisProduct innovation listing for you to stay ahead of the curve Key Attributes Report AttributeDetailsNo. of Pages80Forecast Period2024-2030Estimated Market Value (USD) in 2024$10.83 billionForecasted Market Value (USD) by 2030$20.18 billionCompound Annual Growth Rate10.8%Regions CoveredUnited States Key Topics CoveredChapter 1. Methodology and Scope Chapter 2. Executive Summary 2.1. Market Snapshot2.2. Segment Snapshot2.3. Competitive Landscape SnapshotChapter 3. U.S. Cancer Biopsy Market Variables, Trends, & Scope 3.1. Market Lineage Outlook3.2. Market Dynamics3.2.1. Market Driver Analysis3.2.2. Market Restraint Analysis3.3. Business Environment Analysis3.3.1. Industry Analysis - Porter's Five Forces Analysis3.3.2. PESTLE AnalysisChapter 4. U.S. Cancer Biopsy Market: Type Business Analysis4.1. Type Market Share, 2024 & 20304.2. Type Segment Dashboard4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)4.4. Fine-needle Aspiration4.5. Core Biopsy4.6. Surgical Biopsy4.7. Skin Biopsy /Punch Biopsy4.8. Others Chapter 5. U.S. Cancer Biopsy Market: Cause (Application) Business Analysis5.1. Cause (Application) Market Share, 2024 & 20305.2. Cause (Application) Segment Dashboard5.3. Market Size & Forecasts and Trend Analysis, by Cause (Application), 2018 to 2030 (USD Billion)5.4. Screening & Monitoring5.5. Diagnostics5.6. Investigational & Translational Research5.7. Pharma & Biopharma Discovery & Development Chapter 6. U.S. Cancer Biopsy Market: Site (Organ) Business Analysis6.1. Site (Organ) Market Share, 2024 & 20306.2. Site (Organ) Segment Dashboard6.3. Market Size & Forecasts and Trend Analysis, by Site (Organ), 2018 to 2030 (USD Billion)6.4. Liver6.5. Breast6.6. Thyroid6.7. Prostate Gland6.8. Uterus & Cervix6.9. Kidney6.10. Bladder6.11. Lungs6.12. Pancreas6.13. Others Chapter 7. Competitive Landscape7.1. Participant Overview7.2. Company Market Position Analysis7.3. Company Categorization7.4. Strategy Mapping7.5. Company Profiles/Listing7.5.1. BD (Becton, Dickinson and Company)7.5.2. IZI Medical Products7.5.3. Johnson & Johnson Services, Inc.7.5.4. Argon Medical Devices7.5.5. SPECTRA MEDICAL DEVICES, LLC7.5.6. Medtronic7.5.7. Boston Scientific Corporation7.5.8. CONMED Corporation7.5.9. INRAD, Inc.7.5.10. Thermo Fisher Scientific Inc. For more information about this report visit https://www.researchandmarkets.com/r/dgjzb6 About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. U.S. Cancer Biopsy Market U.S. Cancer Biopsy Market U.S. Cancer Biopsy Market

Related News